{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"078-602-449-566-150","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"078-602-449-566-150","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11813,"type":"PATENT","title":"University of Aberdeen Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":27926,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8443,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: univ* aberdeen. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1658
Search Applicants and Owners separately: univ* aberdeen. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1658
(a) the sum of glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues constitutes more than about 80% of the total amino acid sequence of the XTEN; and\n
(b) the XTEN sequence is substantially non-repetitive such that (i) the XTEN sequence contains no three contiguous amino acids that are identical unless the amino acids are serine residues, or (ii) at least 80% of the XTEN sequence comprises non-overlapping sequence motifs, each of the sequence motifs comprising from 9 to 14 amino acid residues, wherein any two contiguous amino acid residues does not occur more than twice in each of the sequence motifs."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The XTEN of claim 1, wherein the XTEN is further characterized in that:\n
(a) the sum of asparagine and glutamine residues is less than 10% of the total amino acid sequence of the XTEN;\n
(b) the sum of methionine and tryptophan residues is less than 2% of the total amino acid sequence of the XTEN; and/or\n
(c) no one type of amino acid constitutes more than 30% of the XTEN sequence."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The XTEN of claim 1, wherein the XTEN has a subsequence score of less than 10."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The XTEN of claim 1, wherein the XTEN is further characterized in that:\n
(a) the sequence motifs comprises four or more types of amino acids selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P); and\n
(b) the XTEN enhances pharmacokinetic properties of a biologically active protein (BP) when linked to the BP as a fusion protein wherein the pharmacokinetic properties are ascertained by measuring the blood concentration of the fusion protein after administration of a therapeutically effective dose to a subject in comparison to the corresponding BP not linked to XTEN and administered to a subject at a comparable dose."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The XTEN of claim 4, wherein the enhanced pharmacokinetic property is selected from an increase in terminal half-life of at least three-fold and blood concentrations that remain within the therapeutic window for the fusion protein for a period at least about three-fold longer compared to the corresponding BP not linked to XTEN."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The XTEN of claim 1, wherein the XTEN comprises an amino acid sequence at least 95% identical to SEQ ID NO:188, SEQ ID NO:204, SEQ ID NO:206, SEQ ID NO:210, SEQ ID NO:213, SEQ ID NO:215, SEQ ID NO:217, SEQ ID NO:387, SEQ ID NO:391, SEQ ID NO:393, SEQ ID NO:396, SEQ ID NO: 570, or SEQ ID NO:577."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["An isolated fusion protein, comprising the XTEN of claim 1 or 6 linked to a BP."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The isolated fusion protein of claim 7, wherein the BP is selected from the group consisting of a glucose regulating peptide, a metabolic protein, and a growth hormone."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The isolated fusion protein of claim 8, wherein the glucose regulating peptide is exendin-4."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The isolated fusion protein of claim 7, wherein the BP is metabolic protein."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The isolated fusion protein of claim 7, wherein the BP is a growth hormone."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The isolated fusion protein of claim 7, further comprising a second XTEN sequence."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The isolated fusion protein of claim 7, further comprising a spacer sequence between the BP and XTEN, wherein the spacer sequence comprises between 1 to about 50 amino acid residues and optionally comprises a cleavage sequence."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The isolated fusion protein of claim 13, wherein the cleavage sequence is susceptible to cleavage by a protease selected from FXIa, FXIIa, kallikrein, FVIIa, FIXa, FXa, thrombin, elastase-2, granzyme B, MMP-12, MMP-13, MMP-17 or MMP-20, TEV, enterokinase, rhinovirus 3C protease, and sortase A."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition comprising the fusion protein of claim 7, and at least one pharmaceutically acceptable carrier."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["A kit, comprising a container comprising the pharmaceutical composition of claim 15, and instructions for the reconstitution and/or administration of the pharmaceutical composition to a subject."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The XTEN of claim 1, wherein the XTEN comprises SEQ ID NO:188, SEQ ID NO:204, SEQ ID NO:206, SEQ ID NO:210, SEQ ID NO:213, SEQ ID NO:215, SEQ ID NO:217, SEQ ID NO:387, SEQ ID NO:391, SEQ ID NO:393, SEQ ID NO:396, SEQ ID NO: 570, or SEQ ID NO:577."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The XTEN of claim 1, wherein the XTEN comprises SEQ ID NO:373, SEQ ID NO:375, SEQ ID NO:377, SEQ ID NO:378, SEQ ID NO:382, SEQ ID NO:384, SEQ ID NO:388, SEQ ID NO:389, SEQ ID NO:398, SEQ ID NO:401, SEQ ID NO:402, SEQ ID NO:403, SEQ ID NO:409, SEQ ID NO:762, SEQ ID NO:764, SEQ ID NO:765, SEQ ID NO:766, SEQ ID NO:767, or SEQ ID NO:768."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The XTEN of claim 1, wherein the XTEN comprises SEQ ID NO: 204 or SEQ ID NO: 206."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["An extended recombinant polypeptide (XTEN) comprising an amino acid sequence which is SEQ ID NO:188, SEQ ID NO: 204, SEQ ID NO: 206, SEQ ID NO:563, SEQ ID NO:566, SEQ ID NO:569, SEQ ID NO:574, SEQ ID NO:577, SEQ ID NO:585, SEQ ID NO:590, SEQ ID NO:596, SEQ ID NO:597, SEQ ID NO:599, wherein the XTEN is characterized in that:\n
(a) the sum of glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues constitutes more than about 80% of the total amino acid sequence of the XTEN; and\n
(b) the XTEN sequence is substantially non-repetitive such that (i) the XTEN sequence contains no three contiguous amino acids that are identical unless the amino acids are serine residues, or (ii) at least 80% of the XTEN sequence comprises non-overlapping sequence motifs, each of the sequence motifs comprising from 9 to 14 amino acid residues, wherein any two contiguous amino acid residues do not occur more than twice in each of the sequence motifs."],"number":20,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}